|
| Press Releases |
|
 |
|
| Friday, April 1, 2022 |
|
|
Eisai Announces Acquisition of Arteryex Shares (Making Arteryex a Subsidiary) to Strengthen and Rapidly Expand the Foundation of its Digital Solution Business |
| Eisai Co., Ltd. announced today that Eisai has acquired a majority of the shares issued by Arteryex Inc., a company that plans and develops software related to digital solutions such as provision of medical information platforms, through purchase of shares and subscription of a third-party allocation of common shares, and made it a subsidiary, as of March 31, 2022. more info >> |
|
|
エーザイ、デジタルソリューションビジネスの基盤強化と迅速な拡大をめざしたArteryexの株式取得（子会社化）に関するお知らせ |
| エーザイ株式会社は、このたび、医療情報プラットフォームの提供をはじめとしたデジタルソリューションに関するソフトウェア企画・開発会社である Arteryex 株式会社について、株式買取ならびに第三者割当増資の引受けによって過半数の株式を取得し、2022 年3 月 31 日付で子会社化したことお知らせします。 more info >> |
|
| Monday, March 28, 2022 |
|
|
Eisai: Announcement About an Approval for Additional Indication of Jyseleca, JAK inhibitor |
| Gilead Sciences K.K., Eisai Co., Ltd. and EA Pharma Co., Ltd. announced that Gilead acquired an approval of additional indication of Jyseleca, Janus Kinase (JAK) inhibitor, for the treatment of patients with active moderate-to-severe ulcerative colitis in Japan. more info >> |
|
|
ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得 |
| ギリアド・エーザイ・EAファーマ、JAK阻害剤「ジセレカ(R)錠」について、既存治療で効果不十分な中等症から重症の潰瘍性大腸炎の適応追加承認を取得 more info >> |
|
| Tuesday, March 22, 2022 |
|
|
エーザイとバイオジェン、抗アミロイドβ（Aβ）プロトフィブリル抗体レカネマブに関する最新の知見を第16回アルツハイマー・パーキンソン病学会（AD/PD(TM) 2022）において発表 |
| more info >> |
|
|
Eisai: Latest Findings on Lecanemab Presented at AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. and Biogen Inc. announced today that the latest findings on lecanemab, an investigational anti-amyloid-beta (Abeta) protofibril antibody being developed for the treatment of early Alzheimer's disease (AD), were presented at the Abeta Targeted Therapies in AD 2 Symposium at the 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) March 15-20 in Barcelona, Spain and virtually. more info >> |
|
| Wednesday, March 16, 2022 |
|
|
バイオジェンとエーザイはアルツハイマー病治療薬の提携契約を変更 |
| バイオジェン・インク（Nasdaq: BIIB、本社：米国マサチューセッツ州 ケンブリッジ、CEO：ミシェル・ヴォナッソス、以下 バイオジェン）とエーザイ株式会社（本社：東京都、代表執行役CEO：内藤晴夫、以下 エーザイ）は、このたび、既存のアデュカヌマブ（米国の製品名ADUHELM）のコラボレーション契約を変更したことをお知らせします。 more info >> |
|
| Tuesday, March 15, 2022 |
|
|
Eisai: Economic Arrangements of Amendment to Alzheimer's Disease Treatment Collaboration Agreement with Biogen |
| Eisai Co., Ltd. announced the following economic arrangements agreed in the amendment to Alzheimer's disease collaboration agreement with Biogen Inc. separately announced today. more info >> |
|
|
Biogen and Eisai Amend Collaboration Agreements on Alzheimer's Disease Treatments |
| Biogen Inc. and Eisai Co., Ltd. announced today that the companies have amended their existing collaboration agreement on aducanumab, which is commercialized in the United States as ADUHELM (aducanumab-avwa). more info >> |
|
| Friday, March 11, 2022 |
|
|
Eisai to Present New Lecanemab Data Exploring Distinct Mechanism of Action and Clinical Outcomes, Disease State (DSE) Symposium, and Other Pipeline Assets at the AD/PD 2022 Annual Meeting |
| Eisai Co., Ltd. announced today the company will present research from its robust Alzheimer's disease (AD) pipeline, including the latest findings on lecanemab, Eisai's investigational anti-amyloid beta (Abeta) protofibril antibody for the treatment of early AD at the AD/PD 2022 International Conference on Alzheimer's and Parkinson's Diseases (AD/PD) from March 15-20 in Barcelona, Spain and virtually. more info >> |
|
|
|
|
|
|
|
|
|
| Latest Press Releases |
|
Wintermar Reports Results for The Full Year Ended 31 December 2025
Mar 17, 2026 18:16: JST
|
|
|
陽光保險公佈2025年度業績：「新陽光策略」深化落地 書寫責任與擔當新篇
Mar 17, 2026 18:12 HKT/SGT
|
|
|
Exito Media Concepts Announces the 30th Edition of the Cyber Security Summit Philippines 2026
Mar 17, 2026 18:07: JST
|
|
|
阳光保险公布2025年度业绩："新阳光战略"深化落地 书写责任与担当新篇
Mar 17, 2026 18:05 HKT/SGT
|
|
|
Founders Metals Added to GDXJ Index; Commences Drilling at Antino North
Mar 17, 2026 17:59 HKT/SGT
|
|
|
The Executive Centre Advances Digital Transformation in Real Estate with AI Agent Integration
Mar 17, 2026 16:03 HKT/SGT
|
|
|
Wintermar Reports Results for The Full Year Ended 31 December 2025
Mar 17, 2026 16:36 JST
|
|
|
三菱重工、無人機に搭載するミッション・オートノミーの開発で飛行実証に成功 米国Shield AI社と協業して、AI開発環境「Hivemind Enterprise」を活用
Mar 17, 2026 13:35: JST
|
|
|
Successful Flight Demonstration of Mission Autonomy Developed for Use in Unmanned Aerial Vehicles
Mar 17, 2026 14:11 JST
|
|
|
華營控股樂見「AI天秤系統」獲建造安全類別獎項 以創新科技推動工地安全高質量發展
Mar 17, 2026 12:14 HKT/SGT
|
|
|
The University of Tokyo and NEC conclude a Strategic Collaboration Agreement to promote a prosperous society where people and AI succeed together
Mar 17, 2026 12:34 JST
|
|
|
NVIDIA Taps 51WORLD as Global L4 Simulation Partner at GTC
Mar 17, 2026 11:02 HKT/SGT
|
|
|
The Executive Centre Advances Digital Transformation in Real Estate with AI Agent Integration
Mar 17, 2026 11:00: JST
|
|
|
英偉達GTC官宣 五一視界成為全球L4智駕仿真合作夥伴 加速推理型自動駕駛開發！
Mar 17, 2026 10:56 HKT/SGT
|
|
|
「高速道路直結型ステーションハブ推進協議会」本格活動開始のお知らせ
Mar 17, 2026 10:30: JST
|
|
|
|
|
More News >> |
|
|
|
|
|
